Yiling Pharmaceuticals: Approval obtained for market application of hydrochloride meclozine chemical raw material

Yiling Pharmaceutical announced that its wholly-owned subsidiary Wanyang Hengshui Pharmaceutical Co., Ltd. has received the "Approval Notice for Application for Marketing of Chemical Raw Materials" issued by the National Medical Products Administration. The application for marketing of "Memantine Hydrochloride" chemical raw materials submitted by Hengshui Wanyang has been approved. Memantine hydrochloride is a voltage-dependent, moderately affinity, non-competitive NMDA receptor antagonist, which can block neuronal damage caused by pathological elevation of glutamate concentration and treat moderate to severe Alzheimer's disease.